Tag: PASO

Blue Horseshoe Stocks: TLRY Recap & More


Tilray, Inc. TLRY

Our first order of business this morning is to just provide a quick recap of our successful options idea from Friday, which we did not provide yesterday due to the release of our Special Report on PASO.(Check that report out if you missed it)

In Friday’s newsletter, we submitted the TLRY Weekly $92.50-95 Calls as potential day-trade candidates, and every single contract in that range provided huge multi-bag gain opportunities!

$92.50 Calls – Range: 2.10-8.30 – Max Gain: 295%
$93 Calls – Range: 2.00-9.20 – Max Gain: 360%
$93.50 Calls – Range: 1.80-5.00 – Max Gain: 178%
$94 Calls – Range: 2.14-9.83 – Max Gain: 359%
$95 Calls – Range: 1.21-8.85 – Max Gain: 631%

OPKO Health, Inc. OPK – Review

The last time we signaled OPK for observation was just a few weeks ago, on December 28th, just as the stock was gapping up off of its annual lows. Following that report, we’ve seen a couple weeks of steady gains, in an overall range from 2.84-3.935. That represents a solid 39% increase, and a good start to the 2019 calendar year.

We’ve also observed CEO Phillip Frost purchasing 15,000 shares out of the open market yesterday, near those highs. The next step for OPK would be to make a run at its 200DMA of 4.12, so we’ll continue to keep it on our radar in the days and weeks ahead.

Extended Watchlist:
PASO, DTEA, FTNW, KTOV, CVM

Blue Horseshoe Stocks: PASO Special Report

Patient Access Solutions, Inc. PASO – Special Report

We’re beginning this fresh trading week with a special report on a stock you’re not going to want to overlook. PASO (PASHealth) operates in the healthcare industry, for which it has adapted a wide array of services to provide solutions in a rapidly changing healthcare environment.

We are focusing upon PASO at an critical time in the company’s development, having only just announced an important step in a series of acquisitions that fall in line with its overall strategy of opening integrated health centers across New York State and in other regions of the country. Just last week, it was announced that the company had acquired a multi-specialty health and wellness facility.

It is the private practice of Dr. Donald Chiappetta in West Babylon, NY, a town on Long Island just a short drive from the company’s other facilities in Plainview NY.  The practice has been in operation for over two decades, and produces annual revenue exceeding $1.5M in serving, on average, more than 2000 patients on a monthly basis.

On the new union forged here in the new year, Dr. Chiappetta commented: “My staff and I are excited to join the Company. Integrating our practice and specialties with the Plainview facility will create a full service offering and offer our patients the ability to access our team of professionals across a larger geographic area.” (>>View Full PR)

Dr. Chiappetta has also been named Chief Operating Officer of PASO, responsible for managing day-to-day operations as well as facilitating growth both organically and through further strategic acquisitions. In addition to his private practice, he has also worked for both NFL, and Olympic athletes.

We are pleased to report that we will be conducting an exclusive interview with Dr. Chiappetta later this week via our Stock Traders Talk channel, so be sure you’re subscribed to our daily newsletter and keep an eye out for that announcement! In the meantime, take a look at why we’re interested in PASO from a technical standpoint on the chart snapshot below.


The recent bullish rise of PASO is sure to have raised some eyebrows, with considerably increased volume over the same time span.  The next key area of resistance for the stock to contend with sits at .0391. We’ll be looking for the PASO to test that area in the days and weeks ahead.
____

FRESH NEWS:
Just hitting the wires this morning is another update to the PASO newsreel.

COMMACK, NY, Jan. 14, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Patient Access Solutions, Inc. (OTC PINK: PASO), a provider of technology and management solutions for the healthcare industry is proud to announce Dr. James Lederer will be joining the Company as the Director of Behavioral Health for the Group. Dr. Lederer will be based at the Plainview, NY Integrated Health facility. (>>View Full PR)
_____

For More Information on PASO Please Visit:
PASHEALTH.COM

BOCX, CIGX & PASO Inside Today’s Penny Stock Newsletter

Patient Access Solutions, Inc. PASO

Two weeks back, we reported that PASO was trading at its 52-week low, and we felt that the bottom was being solidified in place. Trading on Thursday pushed the price of PASO stock to .0009, which incidentally, could have made savvy traders 50-80% in gains.

As if the increased activity wasn’t enough to be satisfied, the company came with some post-market blockbuster news that could help fuel the continuation of momentum to close out the week strong.

PASO is a perfect example of why patience is key, even with some of our shorter-term plays, just a few weeks time can make a big difference.

HAUPPAUGE, N.Y., Sep 08, 2011 (BUSINESS WIRE) — Patient Access Solutions, Inc. (Pink Sheets: PASO), a leading provider of information technology solutions for the healthcare industry is pleased to announce its EMR management & support solution has been engaged and is being deployed with a Florida based hospital group.

The client is the largest faith based, non profit health care organization in Florida to participate in the EHR (Electronic Health Record) program and has a long standing pedigree as a national leader in the adoption of healthcare IT across its network of 6 hospitals comprising of more than 1,500 beds. This engagement serves as part of its continuing commitment to enable excellent quality care and services, will assist its more than 2,000 physicians in the adoption of Electronic Health Records in their private practices through an EHR Donation Program. The initial implementation expects to generate approximately $3 million in gross revenue over the next year for Patient Access Solutions.

Star Scientific, Inc. CIGX

We were discussing CIGX last Wednesday, at which time the PPS was sitting at 2.33. We alluded to the fact that we believed CIGX qualified as a rebound play. The stock did trade sideways for a few days, and now, over the past two days we have begun to witness some slow and steady gains.

On Thursday, CIGX cracked into the top -gainers list for NASDAQ stocks. It is always impressive when a NASDAQ stock can increase in value 7% in a single day.

Autumn was a huge season for this stock last year, when the PPS doubled in just a few short months. We are anxious to see what activity this fall season will bring to CIGX.

BioCurex, Inc BOCX

Yesterday, BOCX had some earth-shattering news, as the stock price compounded by more than 175%, and this, on forty-four times its 3-month average volume.

When momentum stocks like this hit our radar screen, we like to keep them high on our watchlist as heavy movers with a high bounce probability.

This morning, we foresee a possible gap up followed by a pullback, which we see as a good opportunity to get in for a quick flip on the bounce. Ultimately we will be watching BOCX closely for the dust to settle after yesterday’s excitement.

Here is the huge news that caused all this commotion:

BioCurex’s RECAF(TM) Blood Test for Cancer Can Prevent Two Thirds of Unnecessary Prostate Biopsies

RICHMOND, British Columbia, Sep 8, 2011 (GlobeNewswire via COMTEX) — BioCurex Inc. (OTCBB:BOCX) today announced results indicating that its RECAF blood test for cancer can prevent 70% of unnecessary prostate biopsies.

In a study to be presented at the ISOBM (International Society of Oncology and Biomarkers) annual meeting in October, BioCurex compared the performance of RECAF and free-PSA to discriminate prostate cancer from benign prostate hyperplasia (BPH), a common benign condition that requires no surgical treatment. The RECAF test outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.